Clinical trials are a milestone in the development of safe and effective drugs and therapies. An antibody developed by Helmholtz Munich is now entering a phase 1 clinical trial. Together with the radiopharmaceutical company ITM Isotope Technologies…
Matthias Tschöp, CEO of Helmholtz Munich, talks about translating scientific discoveries into clinical practice, about ambitious targets, and about ideas he acquired during his time in the USA.
The medical technology company Dermagnostix GmbH is a joint spin-off of Helmholtz Munich, the Technical University (TU) Munich and Hahn-Schickard. Its goal: to redefine molecular diagnostics in dermatology. Dermagnostix has now qualified as one of 30…
Researchers at Helmholtz Munich are working toward a world without diabetes. They are not doing so alone, but with a network of organizations, hospitals, and pharmaceutical companies. Their goal is to use experts’ knowledge to create something new:…
A team of researchers from Helmholtz Munich, the German Center for Diabetes Research (DZD) and Novo Nordisk have developed a new hormone combination for the future treatment of type 2 diabetes. The scientists have combined the blood sugar-reducing…
A clinical study confirms the success of a novel technology developed by Helmholtz Munich and the Technical University of Munich (TUM) for the evaluation of the treatment of psoriasis. With the new method, doctors can look deeper into the skin of…
We use cookies to improve your experience on our Website. We need cookies to continually improve our services, enable certain features, and when we embed third-party services or content, such as the Vimeo video player or Twitter feeds. In such cases, information may also be transferred to third parties. By using our website, you agree to the use of cookies. We use different types of cookies. You can personalize your cookie settings here: